Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis

@article{Manouchehrinia2012CostEffectivenessOD,
  title={Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis},
  author={Ali Manouchehrinia and Cris S. Constantinescu},
  journal={Current Neurology and Neuroscience Reports},
  year={2012},
  volume={12},
  pages={592-600}
}
Multiple sclerosis (MS) is a leading cause of disability among young adults and has a significant economic impact on society. Although MS is not currently a curable disease, costly treatments known as disease-modifying therapies (DMTs) are available to reduce the disease impact in certain types of MS. In the current economic downturn, cost-effectiveness analysis (CEA) of therapies in MS has become an important part of the decision-making process in order to use resources efficiently in the face… 
View on Springer
ncbi.nlm.nih.gov
19 Citations
Highly Influential Citations
1
Background Citations
6
Results Citations
1

19 Citations

Citation Type

Citation Type

Pharmacoeconomics of synthetic therapies for multiple sclerosis
TLDR
This review describes the pharmacoeconomic aspects of synthetic therapies for MS and discusses the economic impact of the various classes of licensed disease-modifying treatments (DMTs) for relapsing forms of MS.
Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?
TLDR
The potential contribution of cost-effectiveness analyses to pricing and reimbursement decisions in Europe is assessed and the credibility of the major assumptions contained within the analyses are analyzed.
Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis
TLDR
No differences were found in annualised relapse rates and costs of relapses according to DMT, but a significant difference was observed in total annual costs according to treatment groups (glatiramer acetate being the most expensive), mainly due to differences in unitary costs of alternatives.
Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia
TLDR
None of the DMDs were found to be cost-effective in the treatment of RRMS at a WTP threshold of $100 000 in this analysis, which did not reflect the Saudi population preference in valuation of health states and did not consider the societal perspective in terms of cost.
Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015
TLDR
Higher healthcare costs for treating MS have been associated with a milder disease evolution after 10 years, with possible reduction of long-term non-medical direct and indirect costs.
Social participation in patients with multiple sclerosis: correlations between disability and economic burden
TLDR
Moderate to strong correlations of social participation with clinical status (EDSS), QOL, utility and economic costs encourage exploring better these links in larger cohorts, and the stronger correlation between social participation and QOL than between EDSS and Q OL needs to be confirmed.
Multiple sclerosis: basic knowledge and new insights in perioperative management
TLDR
The disease itself as well as the treatment modalities may have several implications in the conduct of anesthesia and perioperative management of MS patients, and general and regional anesthetic techniques have been successfully used.
Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study
TLDR
The data suggest that regular smoking is associated with more severe disease and faster disability progression, and smoking cessation, whether before or after onset of the disease, isassociated with a slower progression of disability.
Predictors of the 10‐year direct costs for treating multiple sclerosis
TLDR
Predictors of the 10‐year economic burden for DMT administration and management are investigated to investigate the largest direct medical cost for multiple sclerosis.
The association of diet with quality of life, disability, and relapse rate in an international sample of people with multiple sclerosis
TLDR
This study supports significant associations of healthy dietary habits with better physical and mental HRQOL and a lower level of disability and randomized controlled trials of dietary modification for people with MS.
...
1
2
...

References

SHOWING 1-10 OF 75 REFERENCES
Long Term Treatment of Multiple Sclerosis with Interferon-ß May Be Cost Effective
TLDR
An estimate of mean disease progression in patients with MS treated with IFNβ-1a compared with patients who did not receive disease-modifying agents suggested that significant cost savings would be realised after about 12 years’ treatment with IFNs, and the model reported here is based on the hypothesis that the delay in disease progression seen in short term clinical trials is likely to continue if treatment is continued.
Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
TLDR
An Excel-based model was developed to compare the relative effectiveness and cost components of relapses, disability progression, and DMDs in the treatment of RRMS over a 2-year time horizon and found that glatiramer acetate had the least favorable cost-effectiveness and interferon betas had the most favorable costs per relapse avoided.
Pharmacoeconomic Considerations in the Treatment of Multiple Sclerosis
TLDR
The results of the cost effectiveness of drug interventions were mixed, although the findings for natalizumab appear favourable compared with other drugs, and limited evidence on glatiramer acetate suggests that this may be cost effective.
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
TLDR
Use of DMT in MS results in health gains that come at a very high cost, compared to treating patients with all levels of disease, and starting DMT earlier was associated with a lower (more favorable) incremental cost-effectiveness ratio compared to initiating treatment at any disease state.
COST-UTILITY ANALYSIS OF INTERFERON BETA-1B IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
TLDR
Cost-effectiveness analysis in SPMS requires that the effect of treatment beyond clinical trials be included, and analysis should be done from a societal perspective, since many of the costs occur outside the healthcare system.
Treatment of multiple sclerosis with interferon β: an appraisal of cost-effectiveness and quality of life
TLDR
The impact of multiple sclerosis onQoL is substantial and future trials should base outcomes measurement on QoL and be better linked to natural history and cost data.
Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life.
TLDR
The impact of multiple sclerosis onQoL is substantial and future trials should base outcomes measurement on QoL and be better linked to natural history and cost data.
Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis
TLDR
Natalizumab dominated fingolimod in the incremental cost-effectiveness analysis, as it was less costly and more effective in reducing relapses in patients with relapsing MS.
Costs and quality of life in multiple sclerosis
TLDR
Costs and utilities were significantly correlated with functional capacity and the proportion of costs represented by disease modifying drugs is considerably lower than estimated in other studies, as all costs related to the disease are included.
Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis.
TLDR
Evaluating the appropriateness of the clinical data that were selected for Goldberg et al.'s 2009 model of cost-effectiveness in multiple sclerosis and calculating results based on a revised cohort selection method found that IM IFN beta-1a was more cost-effective than in the original analysis, while results for the other first-line disease-modifying drugs remained stable.
...
1
2
3
4
5
...